You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-VEGF Receptor 2 antibody [mV1001.3m-h] (ab42228)

Submit an Abreview Q&A (3)Specific References (1)

Overview

  • Product nameAnti-VEGF Receptor 2 antibody [mV1001.3m-h]See all VEGF Receptor 2 primary antibodies ...
  • Description
    Mouse monoclonal [mV1001.3m-h] to VEGF Receptor 2
  • SpecificityThis antibody shows no cross-reactivity with VEGF Receptor 1.
  • Tested applicationsSandwich ELISA, WB, IP, Functional Studies more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Purified fragment, corresponding to N terminal amino acids 30-200 of Human VEGF Receptor 2

  • Positive controlHuman Umbilical Vein Endothelial Cells (HUVECs).

Applications

Our Abpromise guarantee covers the use of ab42228 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
Sandwich ELISA sELISA: Use a concentration of 5 µg/ml. Can be paired for Sandwich ELISA with Rabbit polyclonal to VEGF Receptor 2 (ab11939). For sandwich ELISA, use this antibody as Capture at 5µg/ml with ab11939 as Detection.
WB WB: Use at an assay dependent dilution. Predicted molecular weight: 151 kDa.
IP IP: Use at an assay dependent dilution.
Functional Studies FuncS: Use a concentration of 5 - 25 µg/ml. This antibody can induce VEGF Receptor 2 tyrosine phosphorylation in Human Umbilical Vein Endothelial Cells (HUVECs).

Target

  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.

    • Target information above from: UniProt accession P35968 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
    • Alternative names
        CD309 antibodyCD309 antigen antibodyFetal liver kinase 1 antibody
        FLK-1 antibodyFLK1 antibodyKDR antibodyKinase insert domain receptor (a type III receptor tyrosine kinase) antibodyKinase insert domain receptor antibodyKRD1 antibodyLy73 antibodyProtein tyrosine kinase receptor FLK1 antibodyProtein-tyrosine kinase receptor flk-1 antibodyTyrosine kinase growth factor receptor antibodyVascular endothelial growth factor receptor 2 antibodyVEGFR 2 antibodyVEGFR antibodyVEGFR-2 antibodyVEGFR2 antibodyVGFR2_HUMAN antibody
      see all

    Anti-VEGF Receptor 2 antibody [mV1001.3m-h] images

    Protocols

    References for Anti-VEGF Receptor 2 antibody [mV1001.3m-h] (ab42228)

    This product has been referenced in:
    • Ptaszynska MM  et al. Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells. Mol Cancer Res 6:352-63 (2008). Read more (PubMed: 18337445) »

    See 1 Publication for this product

    Publishing research using ab42228 ? Please let us know so that we can cite the reference in this datasheet

    Product Wall

    Submit an Abreview for ab42228 Submit a Question for ab42228

    Displaying 1 - 3 of 3 results for Abreviews and Q&A

    10
    Votes: Highest First

    The antibody (ab10972) you have suggested is the one I originally used and it did not work. I need you to suggest another one which is not raised in rabbit but is also not the one I have already bought!
    Please get back to me when you get the other re...

    Read More

    Thank you for your reply. I have now returned to the office an hope I can help further with your enquiry.

    I can now confirm that of the antibodies we have directed against VEGF Receptor 2 (that are not raised in rabbit), most likely to react with...

    Read More

    Is there any news on what would be the best antibody for me to use? Because I am running out of time to do this experiment and I have to undergraduate students kicking their heels until this antibody arrives- any suggestions?

    Sorry to hassel yo...

    Read More

    Thank you for your message which has been forwarded to me as Karin is currently away from the office.

    Reviewing the correspondence on this enquiry so far, I notice Karin has selected some antibodies not raised in rabbit and has been in contact ...

    Read More

    Can the antibody activate VEGFR2 when the sample is a cell lysate?

    Thank you for contacting us.

    I have checked with the lab and they did not try using lysate for the activation assay but are in agreement that this would probably not work due to the presence of detergents and lysis buffer.

    I hope this...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"